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Abstract To improve the efficacy of radiotherapy (RTx),
there is a growing interest in combining RTx with drugs
that inhibit angiogenesis, i.e., the process of neo-vessel
formation out of preexisting capillaries. A frequently used
drug to inhibit angiogenesis is sunitinib (Sutent, SU11248),
a receptor tyrosine kinase inhibitor that is currently FDA
approved for the treatment of several cancer types. The
current review presents an overview of the preclinical
studies and clinical trials that combined sunitinib with
RTx. We discuss the findings from preclinical and clinical
observations with a focus on dose scheduling and com-
monly reported toxicities. In addition, the effects of com-
bination therapy on tumor response and patient survival are
described. Finally, the lessons learned from preclinical and
clinical studies are summarized and opportunities and pit-
falls for future clinical trials are presented.
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Introduction
Radiotherapy (RTx) is effective against many tumor types
and is used for curative and palliative purposes. Conse-
quently, more than half of the cancer patients receive RTx
[1, 2]. Despite improvements in the efficacy of this treat-
ment modality, there are still a considerable number of
patients who show tumor recurrence [1, 3]. To enhance the
clinical benefit of RTx, the current research often aims to
combine RTx with other treatment modalities, including
angiogenesis inhibitors.
Angiogenesis is the process by which new blood vessels
are formed out of preexisting vessels, and it is considered
as one of the hallmarks of cancer [4]. In most tumors, an
imbalance between pro- and anti-angiogenic factors exists
due to tissue hypoxia. This imbalance induces the growth
of an abnormally structured and leaky tumor vasculature
[5]. Consequently, tissue oxygenation remains inadequate
which not only causes continuous stimulation of angio-
genesis but also interferes with RTx. Angiostatic drugs
have been developed to counteract the imbalance between
angioregulatory factors. Several of these drugs were shown
to transiently induce vascular normalization in preclinical
models [5]. Accordingly, the tumor perfusion briefly
improved which was shown to increase the efficacy of RTx
[6–8]. Whether this also occurs in human tumors is still
under investigation.
In the last two decades, combinations of RTx with dif-
ferent angiostatic drugs have been evaluated [6, 9–11]. One
of the frequently used drugs is sunitinib (Sutent, SU11248),
a receptor tyrosine kinase inhibitor (TKI) that targets
multiple receptors, including vascular endothelial growth
factor receptor (VEGFR)-1, 2 and 3, platelet-derived
growth factor receptor (PDGFR) a and b, stem cell growth
factor (c-KIT), fms-like tyrosine kinase receptor 3 (FLT-3),
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neurotropic factor receptor (RET) and colony-stimulating
factor (CSF-1R) [12, 13]. Binding these receptors results in
the inhibition of multiple signaling pathways that are key in
the growth and survival of different tumor cells as well as
of endothelial cell, i.e., the cells that align a blood vessel
(Fig. 1) (for excellent reviews, see [12, 14]). As a result,
sunitinib acts as an effective inhibitor of tumor growth, as
demonstrated in variety of xenograft tumor models. In
patients, sunitinib is approved for the treatment of pan-
creatic neuroendocrine tumors, metastatic renal cell carci-
noma (mRCC) and imatinib-resistant gastrointestinal
stromal tumors. To gain better insight into the applicability
of this combination therapy, we evaluated the preclinical
and clinical studies that combined sunitinib with RTx (for
method of the literature searches, see supplementary data).
We discuss the similarities and discrepancies between
preclinical and clinical observations with a focus on dose
scheduling and commonly reported toxicities. In addition,
the effects on tumor response and patient survival are
described. Finally, the opportunities and pitfalls for future
clinical trials are presented.
Preclinical assessment of combining RTx
with sunitinib
The effects of sunitinib monotherapy on angiogenesis and
tumor growth are well studied and understood [12]. The
effects of sunitinib in combination with RTx are less well
studied, but it has been demonstrated that sunitinib given to
endothelial cells (EC) before RTx enhances the apoptotic
cell fraction [15, 16]. On the other hand, El Kaffas et al.
[17] did not observe an enhanced effect on apoptosis. In
fact, they observed that EC apoptosis was reduced when
sunitinib was combined with high-dose RTx (up to 16 Gy).
These discrepancies are most likely due to differences in
dose scheduling emphasizing that dosing of radiation and
sunitinib are important for their effects on EC apoptosis.
In tumor cells, it is generally observed that the combi-
nation therapy enhances apoptosis and reduces clonogenic
survival. For example, in 4T1 breast cancer cells, the com-
bination resulted in an increase in caspase-mediated apop-
tosis, while both treatments alone had no significant effect
[18]. In two pancreatic adenocarcinoma cell lines (Mia-
PaCa2 and Panc-1), sunitinib combined with RTx decreased
the activation of the Akt and Erk pathway and reduced the
clonogenic survival [11]. Obviously, the responsiveness to
the combination therapy depends on the presence of the
receptors that are inhibited by sunitinib. This was illustrated
in a study using prostate cancer cell lines lacking the target
receptors in which the combination of sunitinib and RTx did
not alter the clonogenic survival compared to RTx alone.
The presence of at least one of the target receptors already
resulted in decreased clonogenic survival during combina-
tion therapy [19]. Collectively, in vitro studies show that
when combined with irradiation, sunitinib can enhance
apoptosis and reduce cell survival in endothelial and tumor
cells. These effects only occur when the treated cells express
Fig. 1 Schematic overview of
the main receptor tyrosine
kinases, the downstream
signaling pathways, and
biological processes that are
targeted by sunitinib
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target receptors for sunitinib and during proper dose
scheduling of both treatment modalities.
An important rationale to combine sunitinib with RTx
was the observation that sunitinib can transiently improve
tumor perfusion by normalizing the tumor vasculature.
During this so-called normalization window, tissue oxy-
genation is increased which improves the efficacy of RTx.
For example, dynamic contrast-enhanced (DCE) MRI
analysis in a xenograft mouse model of kidney cancer
revealed that improved tumor perfusion occurred after
3 days of sunitinib treatment. Applying RTx at day 3 while
sunitinib treatment was continued for another 2 weeks
appeared to further reduce tumor weights compared to
either treatment alone although [20]. In a xenograft mouse
model of squamous cell carcinoma, increased tumor oxy-
genation was observed after 4 days of sunitinib treatment.
Applying RTx at day 4 resulted in a synergistically pro-
longed tumor growth delay as compared to sunitinib or
RTx alone [21]. While these findings indicate that admin-
istration of sunitinib before RTx can improve therapeutic
outcome due to vessel normalization, it has also been
shown that simultaneous (concurrent) administration has
beneficial effects on tumor growth inhibition. For example,
in two studies using different xenograft models of human
pancreatic adenocarcinoma, synergistic interactions on
tumor growth delay were observed after concurrent treat-
ment [11]. This could not be attributed to vascular nor-
malization since a follow-up study using DCE-MRI
showed that a decrease in K(trans), i.e., reduced tissue
perfusion, could predict the anti-tumor effect of the com-
bination therapy [22]. Together with observations in other
xenograft models [18, 23, 24], these findings show that also
concurrent sunitinib can effectively reduce tumor growth.
Most likely, this is related to the increased apoptosis of EC
and tumor cells as observed in the in vitro studies.
Interestingly, in a xenograft prostate cancer model, the
application of sunitinib after RTx is more beneficial
regarding tumor growth delay compared to concurrent
sunitinib [19]. This has also been described in xenograft
models of Lewis lung carcinoma (LLC) [15] and colorectal
carcinoma (HT29) [25]. The mechanisms behind the ben-
eficial effect of sunitinib treatment during or after RTx are
still not fully understood but appear to be distinct from
vessel normalization. A possible explanation might again
be the increased apoptosis as well as the induction of cell
cycle arrest and senescence by sunitinib [26]. In addition, it
is also known that RTx can increase the expression of
vascular growth factors, such as VEGF, thereby inducing a
vascular rebound effect and tumor regrowth [27–29].
Several of these growth factors activate signaling via
receptors that are inhibited by sunitinib. Consequently,
sunitinib given after RTx could counteract this rebound and
thus prevent tumor regrowth.
Finally, an emerging concept that might contribute to
the enhanced anti-tumor effect of the combination therapy
involves the immune system. While describing the mech-
anisms and cells involved in this response is outside the
scope of the current review, both sunitinib and RTx have
been shown to affect many of the cellular players involved
in modulation of the immune response in the tumor
microenvironment [30–37]. Consequently, it is likely that
the combination of both treatment modalities influences the
anti-tumor immune response. However, further research is
needed to elucidate their interaction, to determine the
impact of different treatment schedules and to identify
which immune cells are involved.
In summary, preclinical studies show the feasibility of
combining sunitinib with RTx for cancer treatment. This
involves different mechanisms, including vascular nor-
malization, modulation of cell growth and apoptosis, as
well as the alterations of the immune response. A major
challenge will be to translate these preclinical findings into
clinically relevant treatment protocols.
Lessons learned from combining radiotherapy
with sunitinib in the clinic
Instigated by the promising results of preclinical research,
several phase I and II clinical studies have been performed
to assess the feasibility of combining sunitinib with RTx in
cancer patients (Table 1). It should be noted that while the
preclinical research aimed to elucidate the optimal
scheduling, i.e., sunitinib either before, during, or after
RTx, this has not been properly addressed in clinical trials.
The latter studies focused more on feasibility and toxicity
of the combination therapy, and in most studies, sunitinib
was applied before and during RTx. Furthermore, in sev-
eral studies, sunitinib maintenance therapy was an option
for patients who well tolerated sunitinib treatment. Here,
we focus on the two main schedules of sunitinib treatment
in combination with RTx, i.e., a 6-week cycle (4 weeks on
and 2 weeks off) and continuous administration.
Radiotherapy in combination with 6-week cycle
sunitinib treatment
The standard administration of sunitinib is in 6-week
treatment cycles with 4 weeks of 50 mg/day sunitinib and
2 weeks no treatment [12, 38]. This schedule is generally
well tolerated and would allow patients to recover from the
potential bone marrow toxicities [12]. The most commonly
reported non-hematological adverse effects are gastroin-
testinal toxicities, fatigue, anorexia, hypertension, skin
discoloration, and the hand-foot syndrome. Hematological
toxicities include neutropenia, thrombocytopenia, anemia,
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and leucopenia [38–41]. In general, these adverse effects
are manageable and reversible.
Toxicity
The main concern when combining sunitinib with RTx in
patients is the possible potentiation of the frequency and
severity of side effects. To address this, Kao et al. per-
formed a dose-escalation analysis of sunitinib both before
and during RTx. At the maximum tolerated dose (MTD),
i.e., 10 9 5 Gy IGRT and 37.5 mg sunitinib/day, primar-
ily grade 3 hematological toxicities were observed which
were not reported as dose-limiting toxicities (DLT).
Interestingly, the patients who did experience DLT had
been pretreated with chemotherapy and received RTx for
their liver metastases. They therefore excluded patients
with liver metastasis[6 cm for their follow-up phase II
trials. Although it was stated that sunitinib did not
enhanced RTx toxicities, they observed that RTx enhances
the hematological grade 3/4 toxicities of sunitinib [42]. In
the follow-up phase II trial, the most common grade 3 side
effects were again hematological, while bleeding and liver
function abnormalities occurred once. Although no grade 4
side effects were observed [43], the incidence of the side
effects was higher compared to studies that evaluated RTx
alone [44, 45]. Relatively mild toxicity profiles, including
anemia and thrombocytopenia, were also reported in two
phase II trials in patients with mRCC [46, 47]. Interest-
ingly, the side effects were not potentiated by the combi-
nation. These differences are possibly related to the tumor
type or to the different RTx doses and schedules that were
applied. In addition, the duration of the sunitinib treat-
ment, i.e., single cycle versus multiple cycles, might have
been of influence. For example, in two case reports in
which patients received additional cycles after RTx, the
patients needed dose reduction due to intolerable side
effects [48, 49].
Despite the encouraging toxicity profiles, some severe
toxicities incidentally occur. Tong et al. [43] reported a
grade 5 gastrointestinal hemorrhage and a fatal bron-
chobiliary fistula, possibly related to treatment. The latter
was also described in a case report in a patient who
received sunitinib after thoracic RTx for a subcarinal
metastasis of renal cell carcinoma [50]. Staehler et al.
reported that a patient who was still on treatment with
sunitinib 3 months after stereotactic radiosurgery (SRS)
experienced a fatal cerebral bleeding [47]. Concerns about
combining RTx with sunitinib for brain metastasis in RCC
have been raised in a case report in which a patient
received sunitinib after whole-brain radiotherapy [51].
Altogether, these findings show that the combination
therapy is generally well tolerated, but severe complica-
tions can occur incidentally.
Clinical benefit
While the clinical benefit of the combination therapy has not
been properly evaluated, the results from the phase I/II trials
are encouraging. In patients with oligometastases, Kao et al.
[42] reported complete response (CR) or partial response
(PR) in 59 % of patients. Stable disease (SD) was reached in
28 % of the patients, while progressive disease (PD)
occurred in the remaining patients. These response rates
were favorable compared to systemic therapy alone [42].
This trial was followed by a phase II trial in a comparable
patient group with 2-year follow-up [43]. The 18-month
local control was 75 %, and distant control of 52 %. The
median time until progression was 9.5 months, and at the
end of the study, 18 patients were alive, 11 of whom without
disease [43]. Encouraging results were also observed in
patients with mRCC who received either sunitinib combined
with single-fraction SRS [46] or high-dose hypofractionated
RTx [47]. It was stated that these results were not explained
by the single therapies alone which is supported by several
case reports that described the beneficial effects of this
combination therapy in patients with mRCC [48, 49, 52, 53].
Together, these findings demonstrate that the combination of
sunitinib and RTx might induce clinical responses in dif-
ferent tumor types. However, a phase III clinical trial is
required in order to draw firm conclusions.
Overall, the toxicities of the concurrent combination of
RTx and sunitinib administered in 6-week cycles appears to
depend on the duration and dose of sunitinib treatment, on
the concurrent dose of RTx, but also on previous chemora-
diation and type of metastases, e.g., liver or brain. Never-
theless, the combination therapy is generally well tolerated
and appears to result in encouraging anti-tumor and clinical
responses in a diverse range of tumors. All this warrants
additional studies to further establish the clinical benefit of
the combination therapy and to address the importance of
dose scheduling on treatment efficacy and toxicity.
Radiotherapy in combination with continuous
sunitinib treatment
The disadvantage of interrupting the sunitinib treatment is
that it potentially allows proliferation of tumor cells between
the cycles. For this reason, continuous dosing of monother-
apy sunitinib has also been tested. For this, the daily dose of
sunitinib was reduced to 37.5 mg/day. This regimen is also
well tolerated, with a similar toxicity profile compared to the
4 weeks on and 2 weeks off schedule [12, 54, 55].
Toxicity
Similar to the studies using a 6-week cycle treatment, the
trials combining continuous sunitinib with RTx have
Angiogenesis (2015) 18:385–395 389
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carefully evaluated the toxicity profile. In patients with
localized high-risk prostate cancer, the safe dose of contin-
uous sunitinib in combination with external-beam RTx was
determined at 25 mg/day, at which one out of six patients
developed a DLT (grade 3 fatigue). The most common side
effects were fatigue, neutropenia, anemia, and hypertension
[56]. In a phase II study including patients with locally
advanced hepatocellular carcinoma (HCC), similar common
and manageable side effects were reported when continuous
sunitinib treatment (25 mg/day) was combined with RTx
[57]. This relatively mild toxicity profile is interesting, since
all patients received RTx on the liver and, as stated before,
liver irradiation appeared to be an important factor
decreasing the tolerability of the sunitinib dose [42]. Possi-
bly, the lower dose of sunitinib and the different schedules
underlie the differences in the side effects. However, other
factors such as tumor type and dosing of RTx could also
have contributed, warranting further research.
In a phase I study in patients with primary and metastatic
central nervous system malignancies, the combination of
concurrent sunitinib (37.5 mg/day) and cranial RTx mainly
induced manageable toxicity. The incidence and severity of
the toxicities were independent of type and dose of the RTx
[58]. Since the toxicity rate of the combination treatment
was slightly higher compared to studies in which patients
only received cranial RTx, addition of sunitinib appeared to
enhance the side effects [59, 60]. In a pilot study with
recurrent high-grade glioma patients, 90 % experienced
grade 1/2 toxicity (mainly hematological), while only one
patient had a DLT (grade 4, oral ulcer) [58]. In a following
phase II study with 12 newly diagnosed, non-resectable
glioblastoma patients, again the most frequently reported
side effects were grade 1/2, although some grade 3 toxicities
were reported [61]. However, since only two patients
received the combined therapy, this should be evaluated as
sunitinib monotherapy. With this in mind, sunitinib treat-
ment was stated to be well tolerated but did not result in
anti-tumor responses [61]. Comparable results were found in
glioma patients who received continuous sunitinib as
monotherapy prior to RTx and/or chemotherapy [62].
In contrast to the mild toxicities described so far, a phase
I/II study in patients with soft tissue sarcoma was closed
prematurely due to DLT when sunitinib was combined
with RTx [63]. Seven patients had received 50 mg daily for
2 weeks before RTx, followed by 25 mg daily during RTx.
Dose-limiting toxicities were observed in four patients
(grade 3/4). Subsequently, the starting dose of sunitinib
was reduced to 37.5 mg daily, followed by 37.5 mg daily
during RTx. The next two patients showed DLTs (grade 3),
which led to premature closure of the study. Because of the
lack of clinical benefit and the majority of patients showing
DLTs, the schedule and dosing of sunitinib and RTx was
not recommended in this patient group [63].
Altogether, continuous dosing of sunitinib combined
with RTx is generally well tolerated, although due to tox-
icities, a lower daily dose for sunitinib is usually required
as compared to the 6-week cycle. Furthermore, for specific
tumor types, this combination is not recommended as it
will induce DLT and does not improve patient outcome.
Clinical benefit
Similar to the 6-week cycle treatment, the phase I/II trials
that combine continuous sunitinib with RTx show encour-
aging results. A study in prostate cancer patients with a
median follow-up of 19.6 months showed a median post-
treatment PSA of\0.1 ng/ml. Only two out of 17 patients
showed treatment failure [56]. The suggestion of clinical
benefit was also reported in patients with recurrent high-
grade glioma [58] as well as in patients with primary and
metastatic central nervous system malignancies [64]. In the
latter study, the 6-month PFS was higher compared to
studies that applied cranial RTx alone for patients with brain
metastasis [65, 66]. Promising clinical responses were also
observed in a study with locally advanced HCC patients
[57]. Interestingly, several patients continued sunitinib
treatment until disease progression. The median time to
progression in these patients was 10 months compared to
4 months in those who did not receive maintenance sunitinib
[57]. This observation corresponds with results described in
preclinical studies, where maintenance therapy was the main
factor contributing to tumor growth reduction [19, 26, 67].
While several studies indicated a potential benefit of the
combination therapy, less promising responses were
reported in a phase II study with glioblastoma patients in
which sunitinib was started 8 weeks before RTx [61]. Only
41.7 % of patients completed the 8 weeks of sunitinib prior
to RTx due to tumor progression and neurological deteri-
oration. Furthermore, none of the patients was alive after
1 year [61]. A lack of additional clinical benefit was also
observed in a phase I/II study with soft tissue sarcoma
patients [63].
Together, these studies demonstrate that—similar to
6-week cycle treatment—continuous sunitinib treatment
combined with RTx can induce clinical responses. Also in
line with 6-week cycle treatment, the response appears to
depend on the tumor type and dose scheduling. Interestingly,
it is suggested that mainly the maintenance sunitinib treat-
ment contributes to better and longer disease responses.
Future prospects: lessons to be learned
The results of the preclinical research and clinical trials
have provided valuable insights into the feasibility to
combine sunitinib with RTx. Furthermore, several clinical
390 Angiogenesis (2015) 18:385–395
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trials are ongoing (Table 2) that will further address the
clinical applicability of this combination therapy. Espe-
cially with regard to dose scheduling and toxicity lessons
have to be learned. Although the combination therapy
appears to be well tolerated, the MTD of sunitinib depends
on the scheduling that is used. Compared to the common
dose for sunitinib monotherapy, i.e., 50 mg/day, the com-
bination with RTx requires dose reductions to 37.5 mg/day
in case of a 6-week cycle treatment and 25 mg/day for
continuous administration [42, 43, 56, 57]. While such dose
reductions generally resulted in lower toxicity rates [42,
47], there are still concerns regarding rare but severe side
effects, such as perforations in the gastrointestinal tract or
severe hemorrhages. Interestingly, it has been described in
case reports that dose reductions do not affect tumor
responses [48, 49], possibly because sunitinib is known to
accumulate in the tumor [25]. This is also supported by our
recent preclinical study in which sunitinib dose reductions
of 50 % did not affect the tumor growth delay in combi-
nation with RTx [67]. Dose reduction of sunitinib would
not only reduce the severity and frequency of side effects,
but also lower the financial burden on the healthcare sys-
tem [68]. Therefore, future research should further resolve
whether low-dose sunitinib treatment, i.e., dosing below
the MTD, would affect the response rates in patients.
Measurements of tumor perfusion during treatment could
be of value to get better insight into the dose–response
relationship. Regarding this, an ongoing phase I study
(Table 2, NCT01308034) performs DCE-ultrasonography
(DCE-US) after start of sunitinib to measure neo-angio-
genesis. These data can provide valuable insights into the
dose-dependent intra-tumoral effects of sunitinib on per-
fusion and angiogenesis.
Another important lesson to be learned concerns the
proper scheduling of both treatment modalities. Sunitinib
treatment is often applied several weeks before RTx. This
might be beneficial since sunitinib treatment has been
shown to induce transient vascular normalization in pre-
clinical models, resulting in improved tumor oxygenation
[20, 21, 69]. However, evidence for such a response in
patients should be addressed by future trials, for example
with perfusion measurements using DCE-MRI [70–72] or
by hypoxia imaging techniques such as FMISO PET [73,
74]. On the other hand, in the preclinical models, vascular
normalization occurs rapidly after the start of treatment and
lasts for only a few days. This suggests that even when
vascular normalization occurs in the clinical setting, the
window of opportunity has already passed when sunitinib
treatment is given for several weeks prior to RTx. This is
supported by a study of Lewin et al. [63] where DCE-MRI
and FAZA-PET/CT analyses showed decreased tumor
perfusion and increased tumor hypoxia after 2 weeks of
sunitinib.
While the clinical benefit of sunitinib treatment prior to
RTx is still unclear, there is ample preclinical evidence
supporting a beneficial role of sunitinib maintenance ther-
apy after RTx [15, 19, 57]. The mechanisms responsible for
this are poorly understood but appear to be distinct from
vessel normalization. Possibly, sunitinib counteracts the
vascular rebound effect induced by RTx or improves the
anti-tumor immune response. Unraveling these mecha-
nisms requires further research. Furthermore, most clinical
trials in which patients received maintenance sunitinib did
not report on differences in tumor response rates or sur-
vival compared to patients who did not continue sunitinib
treatment [42, 43, 46, 64]. This provides an opportunity for
future research, and several ongoing studies have included
sunitinib treatment after RTx (Table 2). These studies
might give more insight into the potentially favorable
effect of sunitinib maintenance therapy.
Another unexplored area in scheduling is the interaction
between both treatment modalities when sunitinib has been
part of a previous treatment regime. It has not been
established whether RTx can be applied safely after long-
term sunitinib treatment, whether sunitinib treatment has to
be discontinued, or whether continuation improves tumor
outcome. It has been shown in mRCC patients that dis-
continuation of sunitinib rapidly results in an angiogenic
rebound [75]. Whether this happens in other tumor types as
well and how this affects the efficacy and toxicity of sub-
sequent RTx should be further addressed.
Of note, while the current review is focused on com-
bining sunitinib with RTx, many of the future challenges
reported here for sunitinib, also apply to other angiogenesis
inhibitors. Differences in dose scheduling, type of drug,
and tumor type will influence the therapeutic efficacy [76].
For example, the combination of bevacizumab (anti-VEGF
antibody) and RTx can induce encouraging response rates
[77, 78] or increased toxicity without any response [79,
80]. Similar divergent responses have been described for
the combination of RTx with sorafenib, a TKI that targets
several angiogenesis-related proteins, including VEGFR,
PDGFR, and Raf kinases [81–83]. Unraveling the simi-
larities and differences when combining angiostatic drugs
with RTx requires a more systematic preclinical and clin-
ical approach including, for example, imaging techniques
to measure perfusion and early tumor responses [84].
In conclusion, the combination of sunitinib and RTx is a
promising treatment strategy which deserves further pre-
clinical and clinical investigation. Given the observed
increased side effects of this combination therapy, research
should focus on determining the maximum effective dose
of sunitinib as well as on deciphering the optimal treatment
schedules of the combination therapy. With all the lessons
learned and lessons to be learned, the translation of the
insights from phase I/II clinical trials into clinical phase III
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trials will reveal whether this combination therapy is really
beneficial and could be implemented in daily clinical
practice.
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Creative Commons Attribution 4.0 International License (http://crea
tivecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a
link to the Creative Commons license, and indicate if changes were
made.
References
1. Bernier J, Hall EJ, Giaccia A (2004) Radiation oncology: a
century of achievements. Nat Rev Cancer 4:737–747
2. Delaney G, Jacob S, Featherstone C, Barton M (2005) The role of
radiotherapy in cancer treatment: estimating optimal utilization
from a review of evidence-based clinical guidelines. Cancer
104:1129–1137
3. Begg AC, Stewart FA, Vens C (2011) Strategies to improve
radiotherapy with targeted drugs. Nat Rev Cancer 11:239–253
4. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next
generation. Cell 144:646–674
5. Jain RK (2005) Normalization of tumor vasculature: an emerging
concept in antiangiogenic therapy. Science 307:58–62
6. Dings RP, Loren M, Heun H, McNiel E, Griffioen AW, Mayo
KH, Griffin RJ (2007) Scheduling of radiation with angiogenesis
inhibitors anginex and avastin improves therapeutic outcome via
vessel normalization. Clin Cancer Res 13:3395–3402
7. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev
I, Xu L et al (2004) Kinetics of vascular normalization by
VEGFR2 blockade governs brain tumor response to radiation:
role of oxygenation, angiopoietin-1, and matrix metallopro-
teinases. Cancer Cell 6:553–563
8. McGee MC, Hamner JB, Williams RF, Rosati SF, Sims TL, Ng
CY, Gaber MW et al (2010) Improved intratumoral oxygenation
through vascular normalization increases glioma sensitivity to
ionizing radiation. Int J Radiat Oncol Biol Phys 76:1537–1545
9. Gorski DH, Mauceri HJ, Salloum RM, Gately S, Hellman S,
Beckett MA, Sukhatme VP et al (1998) Potentiation of the
antitumor effect of ionizing radiation by brief concomitant
exposures to angiostatin. Cancer Res 58:5686–5689
10. Zips D, Krause M, Hessel F, Westphal J, Bruchner K, Eicheler
W, Dorfler A et al (2003) Experimental study on different com-
bination schedules of VEGF-receptor inhibitor PTK787/
ZK222584 and fractionated irradiation. Anticancer Res
23:3869–3876
11. Cuneo KC, Geng L, Fu A, Orton D, Hallahan DE, Chakravarthy
AB (2008) SU11248 (sunitinib) sensitizes pancreatic cancer to
the cytotoxic effects of ionizing radiation. Int J Radiat Oncol Biol
Phys 71:873–879
12. Faivre S, Demetri G, Sargent W, Raymond E (2007) Molecular
basis for sunitinib efficacy and future clinical development. Nat
Rev Drug Discov 6:734–745
13. Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G,
Schreck RE et al (2003) In vivo antitumor activity of SU11248, a
novel tyrosine kinase inhibitor targeting vascular endothelial
growth factor and platelet-derived growth factor receptors:
determination of a pharmacokinetic/pharmacodynamic relation-
ship. Clin Cancer Res 9:327–337
14. Aparicio-Gallego G, Blanco M, Figueroa A, Garcia-Campelo R,
Valladares-Ayerbes M, Grande-Pulido E, Anton-Aparicio L
(2011) New insights into molecular mechanisms of sunitinib-as-
sociated side effects. Mol Cancer Ther 10:2215–2223
15. Schueneman AJ, Himmelfarb E, Geng L, Tan J, Donnelly E,
Mendel D, McMahon G et al (2003) SU11248 maintenance
therapy prevents tumor regrowth after fractionated irradiation of
murine tumor models. Cancer Res 63:4009–4016
16. Zhang HP, Takayama K, Su B, Jiao XD, Li R, Wang JJ (2011)
Effect of sunitinib combined with ionizing radiation on
endothelial cells. J Radiat Res 52:1–8
17. El Kaffas A, Al-Mahrouki A, Tran WT, Giles A, Czarnota GJ
(2013) Sunitinib effects on the radiation response of endothelial
and breast tumor cells. Microvasc Res
18. Zwolak P, Jasinski P, Terai K, Gallus NJ, Ericson ME, Clohisy
DR, Dudek AZ (2008) Addition of receptor tyrosine kinase
inhibitor to radiation increases tumour control in an orthotopic
murine model of breast cancer metastasis in bone. Eur J Cancer
44:2506–2517
19. Brooks C, Sheu T, Bridges K, Mason K, Kuban D, Mathew P,
Meyn R (2012) Preclinical evaluation of sunitinib, a multi-ty-
rosine kinase inhibitor, as a radiosensitizer for human prostate
cancer. Radiat Oncol 7:154
20. Hillman GG, Singh-Gupta V, Al-Bashir AK, Yunker CK, Joiner
MC, Sarkar FH, Abrams J et al (2011) Monitoring sunitinib-
induced vascular effects to optimize radiotherapy combined with
soy isoflavones in murine xenograft tumor. Transl Oncol
4:110–121
21. Matsumoto S, Batra S, Saito K, Yasui H, Choudhuri R, Gadisetti
C, Subramanian S et al (2011) Anti-angiogenic agent sunitinib
transiently increases tumor oxygenation and suppresses cycling
hypoxia. Cancer Res
22. Casneuf VF, Delrue L, van Damme N, Demetter P, Robert P,
Corot C, Duyck P et al (2011) Noninvasive monitoring of ther-
apy-induced microvascular changes in a pancreatic cancer model
using dynamic contrast-enhanced magnetic resonance imaging
with P846, a new low-diffusible gadolinium-based contrast agent.
Radiat Res 175:10–20
23. Bozec A, Sudaka A, Toussan N, Fischel JL, Etienne-Grimaldi
MC, Milano G (2009) Combination of sunitinib, cetuximab and
irradiation in an orthotopic head and neck cancer model. Ann
Oncol 20:1703–1707
24. Yoon SS, Stangenberg L, Lee YJ, Rothrock C, Dreyfuss JM,
Baek KH, Waterman PR et al (2009) Efficacy of sunitinib and
radiotherapy in genetically engineered mouse model of soft-tissue
sarcoma. Int J Radiat Oncol Biol Phys 74:1207–1216
25. Gotink KJ, Broxterman HJ, Labots M, de Haas RR, Dekker H,
Honeywell RJ, Rudek MA et al (2011) Lysosomal sequestration
of sunitinib: a novel mechanism of drug resistance. Clin Cancer
Res 17:7337–7346
26. Zhu Y, Xu L, Zhang J, Hu X, Liu Y, Yin H, Lv T et al (2013)
Sunitinib induces cellular senescence via p53/Dec1 activation in
renal cell carcinoma cells. Cancer Sci 104:1052–1061
27. Dalrymple SL, Becker RE, Zhou H, DeWeese TL, Isaacs JT
(2012) Tasquinimod prevents the angiogenic rebound induced by
fractionated radiation resulting in an enhanced therapeutic
response of prostate cancer xenografts. Prostate 72:638–648
28. Hou H, Lariviere JP, Demidenko E, Gladstone D, Swartz H, Khan
N (2009) Repeated tumor pO(2) measurements by multi-site EPR
oximetry as a prognostic marker for enhanced therapeutic effi-
cacy of fractionated radiotherapy. Radiother Oncol 91:126–131
29. Park JS, Qiao L, Su ZZ, Hinman D, Willoughby K, McKinstry R,
Yacoub A et al (2001) Ionizing radiation modulates vascular
endothelial growth factor (VEGF) expression through multiple
mitogen activated protein kinase dependent pathways. Oncogene
20:3266–3280
Angiogenesis (2015) 18:385–395 393
123
30. Bose A, Taylor JL, Alber S, Watkins SC, Garcia JA, Rini BI, Ko
JS et al (2011) Sunitinib facilitates the activation and recruitment
of therapeutic anti-tumor immunity in concert with specific
vaccination. Int J Cancer 129:2158–2170
31. Dirkx AE, Oude Egbrink MG, Castermans K, van der Schaft DW,
Thijssen VL, Dings RP, Kwee L et al (2006) Anti-angiogenesis
therapy can overcome endothelial cell anergy and promote
leukocyte-endothelium interactions and infiltration in tumors.
FASEB J 20:621–630
32. Shrimali RK, Yu Z, Theoret MR, Chinnasamy D, Restifo NP,
Rosenberg SA (2010) Antiangiogenic agents can increase lym-
phocyte infiltration into tumor and enhance the effectiveness of
adoptive immunotherapy of cancer. Cancer Res 70:6171–6180
33. Huang H, Langenkamp E, Georganaki M, Loskog A, Fuchs PF,
Dieterich LC, Kreuger J et al (2015) VEGF suppresses T-lym-
phocyte infiltration in the tumor microenvironment through
inhibition of NF-kappaB-induced endothelial activation. FASEB
J 29:227–238
34. Shahabi V, Postow MA, Tuck D, Wolchok JD (2015) Immune-
priming of the tumor microenvironment by radiotherapy: ratio-
nale for combination with immunotherapy to improve anticancer
efficacy. Am J Clin Oncol 38:90–97
35. Sharma A, Bode B, Wenger RH, Lehmann K, Sartori AA, Moch
H, Knuth A et al (2011) c-Radiation promotes immunological
recognition of cancer cells through increased expression of can-
cer-testis antigens in vitro and in vivo. PLoS ONE 6:e28217
36. Burnette BC, Liang H, Lee Y, Chlewicki L, Khodarev NN,
Weichselbaum RR, Fu YX et al (2011) The efficacy of radio-
therapy relies upon induction of type I interferon-dependent
innate and adaptive immunity. Cancer Res 71:2488–2496
37. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb
JS, Formenti SC, Demaria S (2009) Fractionated but not single-
dose radiotherapy induces an immune-mediated abscopal effect
when combined with anti-CTLA-4 antibody. Clin Cancer Res
15:5379–5388
38. Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N,
Bello C et al (2006) Safety, pharmacokinetic, and antitumor
activity of SU11248, a novel oral multitarget tyrosine kinase
inhibitor, in patients with cancer. J Clin Oncol 24:25–35
39. Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski
RM, Rixe O, Oudard S et al (2007) Sunitinib versus interferon alfa
in metastatic renal-cell carcinoma. N Engl J Med 356:115–124
40. Motzer RJ, Michaelson MD, Redman BG, Hudes GR, Wilding G,
Figlin RA, Ginsberg MS et al (2006) Activity of SU11248, a
multitargeted inhibitor of vascular endothelial growth factor
receptor and platelet-derived growth factor receptor, in patients
with metastatic renal cell carcinoma. J Clin Oncol 24:16–24
41. Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME,
Shah MH, Verweij J, McArthur G et al (2006) Efficacy and safety
of sunitinib in patients with advanced gastrointestinal stromal
tumour after failure of imatinib: a randomised controlled trial.
Lancet 368:1329–1338
42. Kao J, Packer S, Vu HL, Schwartz ME, Sung MW, Stock RG, Lo
YC et al (2009) Phase 1 study of concurrent sunitinib and image-
guided radiotherapy followed by maintenance sunitinib for
patients with oligometastases: acute toxicity and preliminary
response. Cancer 115:3571–3580
43. Tong CC, Ko EC, Sung MW, Cesaretti JA, Stock RG, Packer SH,
Forsythe K et al (2012) Phase II trial of concurrent sunitinib and
image-guided radiotherapy for oligometastases. PLoS ONE
7:e36979
44. Milano MT, Katz AW, Muhs AG, Philip A, Buchholz DJ, Schell
MC, Okunieff P (2008) A prospective pilot study of curative-
intent stereotactic body radiation therapy in patients with 5 or
fewer oligometastatic lesions. Cancer 112:650–658
45. Salama JK, Chmura SJ, Mehta N, Yenice KM, Stadler WM,
Vokes EE, Haraf DJ et al (2008) An initial report of a radiation
dose-escalation trial in patients with one to five sites of metastatic
disease. Clin Cancer Res 14:5255–5259
46. Staehler M, Haseke N, Nuhn P, Tullmann C, Karl A, Siebels M,
Stief CG et al (2011) Simultaneous anti-angiogenic therapy and
single-fraction radiosurgery in clinically relevant metastases from
renal cell carcinoma. BJU Int 108:673–678
47. Staehler M, Haseke N, Stadler T, Nuhn P, Roosen A, Stief CG,
Wilkowski R (2012) Feasibility and effects of high-dose
hypofractionated radiation therapy and simultaneous multi-kinase
inhibition with sunitinib in progressive metastatic renal cell
cancer. Urol Oncol 30:290–293
48. Choi YR, Han HS, Lee OJ, Lim SN, Kim MJ, Yeon MH, Jeon HJ
et al (2012) Metastatic renal cell carcinoma in a supraclavicular
lymph node with no known primary: a case report. Cancer Res
Treat 44:215–218
49. Hird AE, Chow E, Ehrlich L, Probyn L, Sinclair E, Yip D, Ko YJ
(2008) Rapid improvement in pain and functional level in a
patient with metastatic renal cell carcinoma: a case report and
review of the literature. J Palliat Med 11:1156–1161
50. Basille D, Andrejak M, Bentayeb H, Kanaan M, Fournier C,
Lecuyer E, Boutemy M et al (2010) Bronchial fistula associated
with sunitinib in a patient previously treated with radiation
therapy. Ann Pharmacother 44:383–386
51. Kelly PJ, Weiss SE, Sher DJ, Perez-Atayde AR, Dal Cin P,
Choueiri TK (2010) Sunitinib-induced pseudoprogression after
whole-brain radiotherapy for metastatic renal cell carcinoma.
J Clin Oncol 28:e433–e435
52. Straka C, Kim DW, Timmerman RD, Pedrosa I, Jacobs C, Bru-
garolas J (2013) Ablation of a site of progression with stereotactic
body radiation therapy extends sunitinib treatment from 14 to 22
months. J Clin Oncol 31:e401–e403
53. Venton G, Ducournau A, Gross E, Lechevallier E, Rochwerger A,
Curvale G, Zink JV et al (2012) Complete pathological response
after sequential therapy with sunitinib and radiotherapy for
metastatic clear cell renal carcinoma. Anticancer Res 32:701–705
54. Escudier B, Roigas J, Gillessen S, Harmenberg U, Srinivas S,
Mulder SF, Fountzilas G et al (2009) Phase II study of sunitinib
administered in a continuous once-daily dosing regimen in
patients with cytokine-refractory metastatic renal cell carcinoma.
J Clin Oncol 27:4068–4075
55. George S, Blay JY, Casali PG, le Cesne A, Stephenson P, Dep-
rimo SE, Harmon CS et al (2009) Clinical evaluation of contin-
uous daily dosing of sunitinib malate in patients with advanced
gastrointestinal stromal tumour after imatinib failure. Eur J
Cancer 45:1959–1968
56. Corn PG, Song DY, Heath E, Maier J, Meyn R, Kuban D,
DePetrillo TA et al (2013) Sunitinib plus androgen deprivation
and radiation therapy for patients with localized high-risk pros-
tate cancer: results from a multi-institutional phase 1 study. Int J
Radiat Oncol Biol Phys 86:540–545
57. Chi KH, Liao CS, Chang CC, Ko HL, Tsang YW, Yang KC,
Mehta MP (2010) Angiogenic blockade and radiotherapy in
hepatocellular carcinoma. Int J Radiat Oncol Biol Phys
78:188–193
58. Wuthrick EJ, Curran WJ Jr, Camphausen K, Lin A, Glass J,
Evans J, Andrews DW et al (2014) A pilot study of hypofrac-
tionated stereotactic radiation therapy and sunitinib in previously
irradiated patients with recurrent high-grade glioma. Int J Radiat
Oncol Biol Phys 90:369–375
59. Mehta MP, Rodrigus P, Terhaard CH, Rao A, Suh J, Roa W,
Souhami L et al (2003) Survival and neurologic outcomes in a
randomized trial of motexafin gadolinium and whole-brain radi-
ation therapy in brain metastases. J Clin Oncol 21:2529–2536
394 Angiogenesis (2015) 18:385–395
123
60. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE,
Schell MC, Werner-Wasik M et al (2004) Whole brain radiation
therapy with or without stereotactic radiosurgery boost for
patients with one to three brain metastases: phase III results of the
RTOG 9508 randomised trial. Lancet 363:1665–1672
61. Balana C, Gil MJ, Perez P, Reynes G, Gallego O, Ribalta T,
Capellades J et al (2014) Sunitinib administered prior to radio-
therapy in patients with non-resectable glioblastoma: results of a
phase II study. Target Oncol
62. Neyns B, Sadones J, Chaskis C, Dujardin M, Everaert H, Lv S,
Duerinck J et al (2011) Phase II study of sunitinib malate in
patients with recurrent high-grade glioma. J Neurooncol
103:491–501
63. Lewin J, Khamly KK, Young RJ, Mitchell C, Hicks RJ, Toner
GC, Ngan SY et al (2014) A phase Ib/II translational study of
sunitinib with neoadjuvant radiotherapy in soft-tissue sarcoma.
Br J Cancer 111:2254–2261
64. Wuthrick EJ, Kamrava M, Curran WJ Jr, Werner-Wasik M,
Camphausen KA, Hyslop T, Axelrod R et al (2011) A phase 1b
trial of the combination of the antiangiogenic agent sunitinib and
radiation therapy for patients with primary and metastatic central
nervous system malignancies. Cancer 117:5548–5559
65. Khuntia D, Brown P, Li J, Mehta MP (2006) Whole-brain
radiotherapy in the management of brain metastasis. J Clin Oncol
24:1295–1304
66. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman
T, McKenna WG et al (1997) Recursive partitioning analysis
(RPA) of prognostic factors in three Radiation Therapy Oncology
Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol
Phys 37:745–751
67. Kleibeuker EA, Ten Hooven MA, Castricum KC, Honeywell R,
Griffioen AW, Verheul HM, Slotman BJ et al (2015) Optimal
treatment scheduling of ionizing radiation and sunitinib improves
the antitumor activity and allows dose reduction. Cancer Med (in
press)
68. Hagiwara M, Hackshaw MD, Oster G (2013) Economic burden of
selected adverse events in patients aged C65 years with meta-
static renal cell carcinoma. J Med Econ 16:1300–1306
69. Czabanka M, Vinci M, Heppner F, Ullrich A, Vajkoczy P (2009)
Effects of sunitinib on tumor hemodynamics and delivery of
chemotherapy. Int J Cancer 124:1293–1300
70. Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ,
Harris A et al (2012) Phase I trial of combretastatin A4 phosphate
(CA4P) in combination with bevacizumab in patients with
advanced cancer. Clin Cancer Res 18:3428–3439
71. Yopp AC, Schwartz LH, Kemeny N, Gultekin DH, Gonen M,
Bamboat Z, Shia J et al (2011) Antiangiogenic therapy for pri-
mary liver cancer: correlation of changes in dynamic contrast-
enhanced magnetic resonance imaging with tissue hypoxia
markers and clinical response. Ann Surg Oncol 18:2192–2199
72. Machiels JP, Henry S, Zanetta S, Kaminsky MC, Michoux N,
Rommel D, Schmitz S et al (2010) Phase II study of sunitinib in
recurrent or metastatic squamous cell carcinoma of the head and
neck: GORTEC 2006-01. J Clin Oncol 28:21–28
73. Hugonnet F, Fournier L, Medioni J, Smadja C, Hindie E, Huchet
V, Itti E et al (2011) Metastatic renal cell carcinoma: relationship
between initial metastasis hypoxia, change after 1 month’s
sunitinib, and therapeutic response: an 18F-fluoromisonidazole
PET/CT study. J Nucl Med 52:1048–1055
74. Murakami M, Zhao S, Zhao Y, Chowdhury NF, Yu W, Nishijima
K, Takiguchi M et al (2012) Evaluation of changes in the tumor
microenvironment after sorafenib therapy by sequential histology
and 18F-fluoromisonidazole hypoxia imaging in renal cell car-
cinoma. Int J Oncol 41:1593–1600
75. Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de
Hoog CL, de Jong TA, Vyth-Dreese FA et al (2012) Rapid
angiogenesis onset after discontinuation of sunitinib treatment of
renal cell carcinoma patients. Clin Cancer Res 18:3961–3971
76. Kleibeuker EA, Griffioen AW, Verheul HM, Slotman BJ, Thi-
jssen VL (2012) Combining angiogenesis inhibition and radio-
therapy: a double-edged sword. Drug Resist Updat 15:173–182
77. Blaszkowsky LS, Ryan DP, Szymonifka J, Borger DR, Zhu AX,
Clark JW, Kwak EL et al (2014) Phase I/II study of neoadjuvant
bevacizumab, erlotinib and 5-fluorouracil with concurrent exter-
nal beam radiation therapy in locally advanced rectal cancer. Ann
Oncol 25:121–126
78. Kambadakone A, Yoon SS, Kim TM, Karl DL, Duda DG,
DeLaney TF, Sahani DV (2015) CT perfusion as an imaging
biomarker in monitoring response to neoadjuvant bevacizumab
and radiation in soft-tissue sarcomas: comparison with tumor
morphology, circulating and tumor biomarkers, and gene
expression. AJR Am J Roentgenol 204:W11–W18
79. Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Kamijo A,
Akiba T et al (2015) Phase II study of preoperative concurrent
chemoradiotherapy with S-1 plus bevacizumab for locally
advanced resectable rectal adenocarcinoma. Oncology 88:49–56
80. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishi-
kawa R, Carpentier AF et al (2014) Bevacizumab plus radio-
therapy-temozolomide for newly diagnosed glioblastoma. N Engl
J Med 370:709–722
81. Meyer JM, Perlewitz KS, Hayden JB, Doung YC, Hung AY,
Vetto JT, Pommier RF et al (2013) Phase I trial of preoperative
chemoradiation plus sorafenib for high-risk extremity soft tissue
sarcomas with dynamic contrast-enhanced MRI correlates. Clin
Cancer Res 19:6902–6911
82. Hottinger AF, Aissa AB, Espeli V, Squiban D, Dunkel N, Vargas
MI, Hundsberger T et al (2014) Phase I study of sorafenib
combined with radiation therapy and temozolomide as first-line
treatment of high-grade glioma. Br J Cancer 110:2655–2661
83. Chen SW, Lin LC, Kuo YC, Liang JA, Kuo CC, Chiou JF (2014)
Phase 2 study of combined sorafenib and radiation therapy in
patients with advanced hepatocellular carcinoma. Int J Radiat
Oncol Biol Phys 88:1041–1047
84. Jalali S, Chung C, Foltz W, Burrell K, Singh S, Hill R, Zadeh G
(2014) MRI biomarkers identify the differential response of
glioblastoma multiforme to anti-angiogenic therapy. Neuro Oncol
16:868–879
Angiogenesis (2015) 18:385–395 395
123
